CY1117437T1 - Αντισωματα αντι-μεσοθηλινης και χρησεις αυτων - Google Patents
Αντισωματα αντι-μεσοθηλινης και χρησεις αυτωνInfo
- Publication number
- CY1117437T1 CY1117437T1 CY20161100353T CY161100353T CY1117437T1 CY 1117437 T1 CY1117437 T1 CY 1117437T1 CY 20161100353 T CY20161100353 T CY 20161100353T CY 161100353 T CY161100353 T CY 161100353T CY 1117437 T1 CY1117437 T1 CY 1117437T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibodies
- tumors
- binding domains
- mesothelin
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει ανασυνδυασμένες περιοχές πρόσδεσης αντιγόνου και αντισώματα και λειτουργικά τμήματα που περιέχουν τέτοιες περιοχές πρόσδεσης αντιγόνου που είναι ειδικές για το αγκυροβολημένο στην μεμβράνη, 4O kDa πεπτίδιο της μεσοθηλίνης, το οποίο υπερεκφράζεται σε πολλούς όγκους, όπως παγκρεατικούς και όγκους ωοθηκών, στο μεσοθηλίωμα και σε κύτταρα καρκίνου του πνεύμονα. Αυτά τα αντισώματα, συνεπώς, μπορεί να χρησιμοποιηθούν για να θεραπεύσουν αυτές και άλλες διαταραχές και καταστάσεις. Αντισώματα της εφεύρεσης μπορούν επίσης να χρησιμοποιηθούν στον διαγνωστικό τομέα, καθώς και για περαιτέρω έρευνα του ρόλου της μεσοθηλίνης στην εξέλιξη διαταραχών που σχετίζονται με καρκίνο. Η εφεύρεση παρέχει επίσης αλληλουχίες νουκλεϊκών οξέων που κωδικοποιούν τα προαναφερθέντα αντισώματα, φορείς που περιλαμβάνουν τις ίδιες, φαρμακευτικές συνθέσεις και κιτ με οδηγίες για χρήση.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US437807P | 2007-11-26 | 2007-11-26 | |
EP08855189.0A EP2215121B1 (en) | 2007-11-26 | 2008-11-19 | Anti-mesothelin antibodies and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117437T1 true CY1117437T1 (el) | 2017-04-26 |
Family
ID=40351874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100353T CY1117437T1 (el) | 2007-11-26 | 2016-04-27 | Αντισωματα αντι-μεσοθηλινης και χρησεις αυτων |
Country Status (31)
Country | Link |
---|---|
US (3) | US9023351B2 (el) |
EP (3) | EP2634196A1 (el) |
JP (3) | JP5608091B2 (el) |
KR (1) | KR101559599B1 (el) |
CN (2) | CN101952319B (el) |
AU (1) | AU2008329221B2 (el) |
BR (1) | BRPI0819909B8 (el) |
CA (1) | CA2706529C (el) |
CO (1) | CO6280409A2 (el) |
CR (1) | CR11456A (el) |
CU (1) | CU23833A3 (el) |
CY (1) | CY1117437T1 (el) |
DK (1) | DK2215121T3 (el) |
DO (1) | DOP2010000150A (el) |
EC (1) | ECSP10010191A (el) |
ES (1) | ES2569513T3 (el) |
GT (1) | GT201000148A (el) |
HK (2) | HK1148541A1 (el) |
HN (1) | HN2010001062A (el) |
HR (1) | HRP20160485T1 (el) |
HU (1) | HUE027358T2 (el) |
IL (1) | IL205681A0 (el) |
MA (1) | MA31862B1 (el) |
MX (1) | MX2010005603A (el) |
MY (1) | MY157164A (el) |
NZ (1) | NZ585551A (el) |
PL (1) | PL2215121T3 (el) |
SI (1) | SI2215121T1 (el) |
TN (1) | TN2010000234A1 (el) |
UA (1) | UA106036C2 (el) |
WO (1) | WO2009068204A1 (el) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS53760B1 (en) * | 2007-10-01 | 2015-06-30 | Bristol-Myers Squibb Company | HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES |
AU2008329221B2 (en) * | 2007-11-26 | 2013-11-07 | Bayer Intellectual Property Gmbh | Anti-mesothelin antibodies and uses therefor |
AR076284A1 (es) * | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
EP2655418B1 (en) * | 2010-12-20 | 2017-10-04 | F. Hoffmann-La Roche AG | Anti-mesothelin antibodies and immunoconjugates |
DK3138581T3 (en) | 2011-03-17 | 2019-04-15 | Univ Birmingham | REDIRECTED IMMUNTERY |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US20140127240A1 (en) | 2011-04-21 | 2014-05-08 | Bayer Pharma Aktiengesellschaft | Novel Binder-Drug Conjugates (ADCs) and Use of Same |
WO2014004549A2 (en) * | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
US9416190B2 (en) * | 2012-09-27 | 2016-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
CN103819559B (zh) * | 2013-12-10 | 2016-02-24 | 中国科学院武汉病毒研究所 | 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途 |
PT3086814T (pt) | 2013-12-23 | 2020-09-04 | Bayer Pharma AG | Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp |
SG10201902850TA (en) | 2014-09-30 | 2019-04-29 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
EP3298033B2 (en) | 2015-05-18 | 2023-07-12 | TCR2 Therapeutics Inc. | Compositions and medical uses for tcr reprogramming using fusion proteins |
SG10201908685QA (en) | 2015-06-22 | 2019-10-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
JP2018528759A (ja) * | 2015-06-30 | 2018-10-04 | ヘンリアス バイオテック カンパニー リミテッド | 抗血管内皮増殖因子受容体2(vegfr2)抗体 |
NZ740855A (en) * | 2015-08-21 | 2022-04-29 | Crage Medical Co Ltd | Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin |
KR101782487B1 (ko) * | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
EP3393504A1 (en) | 2015-12-22 | 2018-10-31 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
ES2944597T3 (es) | 2015-12-30 | 2023-06-22 | Novartis Ag | Terapias con células efectoras inmunitarias de eficacia mejorada |
CN108699159B (zh) * | 2016-02-15 | 2022-07-29 | 地方独立行政法人神奈川县立病院机构 | 膜型粘蛋白样蛋白质的识别及其医疗应用 |
WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
BR112018071096A2 (pt) | 2016-04-15 | 2019-02-26 | Novartis Ag | composições e métodos para a expressão da proteína seletiva |
BR112018074453A2 (pt) | 2016-05-27 | 2019-03-19 | Abbvie Biotherapeutics Inc. | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral |
EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
MX2019001469A (es) | 2016-08-01 | 2019-10-02 | Novartis Ag | Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2. |
EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2018048975A1 (en) | 2016-09-09 | 2018-03-15 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
DK3445787T3 (da) | 2016-10-07 | 2021-03-01 | Tcr2 Therapeutics Inc | Sammensætninger og fremgangsmåder til omprogrammering af t-cellereceptorer under anvendelse af fusionsproteiner |
AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
CA3045466A1 (en) | 2016-12-01 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
WO2018114798A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
EP3558388A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen |
JP7030811B2 (ja) | 2016-12-21 | 2022-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ksp阻害剤を有する特異的抗体-薬物コンジュゲート(adc) |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
EP3638295A1 (en) | 2017-06-13 | 2020-04-22 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
JP6339283B1 (ja) | 2017-10-31 | 2018-06-06 | 国立大学法人 岡山大学 | Dna、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体 |
WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
WO2019121906A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
MX2020006666A (es) * | 2017-12-24 | 2020-08-31 | Noile Immune Biotech Inc | Celula inmunocompetente que expresa una molecula de superficie celular que reconoce especificamente la mesotelina humana, il-7 y ccl19. |
EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
US20210253666A1 (en) | 2018-08-30 | 2021-08-19 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
EP3897851A2 (en) | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
SG11202108761YA (en) * | 2019-03-14 | 2021-09-29 | Morphosys Ag | Antibodies targeting c5ar |
WO2020187998A1 (en) | 2019-03-19 | 2020-09-24 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
WO2020234114A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | A novel stable high concentration formulation for anetumab ravtansine |
EP4004040A4 (en) * | 2019-07-29 | 2023-08-16 | Fred Hutchinson Cancer Center | METHODS AND COMPOSITIONS FOR INDUCING NOTCH SIGNALING IN TUMOR MICROOM ENVIRONMENTS |
UY38995A (es) | 2019-12-20 | 2021-06-30 | Amgen Inc | Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos |
WO2021123996A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
AU2021288224A1 (en) | 2020-06-11 | 2023-01-05 | Novartis Ag | ZBTB32 inhibitors and uses thereof |
CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
WO2024089013A1 (en) | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
CA2229043C (en) * | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
WO1997025068A2 (en) | 1996-01-05 | 1997-07-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Mesothelin antigen and methods and kits for targeting it |
EP1025230B1 (en) * | 1997-12-01 | 2006-02-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE |
US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
ES2269105T3 (es) * | 1999-02-26 | 2007-04-01 | Pacific Northwest Research Institute | Metodos y composiciones para el diagnostico de carcinomas. |
CA2347973C (en) | 1999-07-20 | 2010-06-22 | Morphosys Ag | Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds |
AU2006223301B2 (en) | 2005-03-10 | 2010-11-04 | Eisai, Inc. | Anti-mesothelin antibodies |
US20090047211A1 (en) * | 2005-05-12 | 2009-02-19 | The Govt. Of The U.S. As Represented By The Sec. Of The Dept. Of Health And Human Services | Anti-mesothelin antibodies useful for immunological assays |
NZ564027A (en) | 2005-05-18 | 2011-06-30 | Morphosys Ag | Anti-GM-CSF antibodies and uses therefor |
KR20080031001A (ko) * | 2005-06-02 | 2008-04-07 | 아스트라제네카 아베 | Cd20에 대한 항체 및 그의 용도 |
RS53760B1 (en) * | 2007-10-01 | 2015-06-30 | Bristol-Myers Squibb Company | HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES |
AU2008329221B2 (en) * | 2007-11-26 | 2013-11-07 | Bayer Intellectual Property Gmbh | Anti-mesothelin antibodies and uses therefor |
-
2008
- 2008-11-19 AU AU2008329221A patent/AU2008329221B2/en active Active
- 2008-11-19 BR BRPI0819909A patent/BRPI0819909B8/pt active IP Right Grant
- 2008-11-19 EP EP13168583.6A patent/EP2634196A1/en not_active Ceased
- 2008-11-19 PL PL08855189T patent/PL2215121T3/pl unknown
- 2008-11-19 EP EP08855189.0A patent/EP2215121B1/en active Active
- 2008-11-19 HU HUE08855189A patent/HUE027358T2/en unknown
- 2008-11-19 NZ NZ585551A patent/NZ585551A/en unknown
- 2008-11-19 DK DK08855189.0T patent/DK2215121T3/en active
- 2008-11-19 SI SI200831603A patent/SI2215121T1/sl unknown
- 2008-11-19 CN CN200880125390.8A patent/CN101952319B/zh active Active
- 2008-11-19 KR KR1020107011375A patent/KR101559599B1/ko active IP Right Grant
- 2008-11-19 US US12/744,849 patent/US9023351B2/en active Active
- 2008-11-19 CA CA2706529A patent/CA2706529C/en active Active
- 2008-11-19 CN CN201410396441.8A patent/CN104151429B/zh active Active
- 2008-11-19 MX MX2010005603A patent/MX2010005603A/es active IP Right Grant
- 2008-11-19 JP JP2010535269A patent/JP5608091B2/ja active Active
- 2008-11-19 ES ES08855189.0T patent/ES2569513T3/es active Active
- 2008-11-19 UA UAA201008006A patent/UA106036C2/uk unknown
- 2008-11-19 EP EP16170412.7A patent/EP3103814A1/en not_active Withdrawn
- 2008-11-19 WO PCT/EP2008/009756 patent/WO2009068204A1/en active Application Filing
- 2008-11-19 MY MYPI2010002379A patent/MY157164A/en unknown
-
2010
- 2010-05-11 IL IL205681A patent/IL205681A0/en active IP Right Grant
- 2010-05-20 GT GT201000148A patent/GT201000148A/es unknown
- 2010-05-20 DO DO2010000150A patent/DOP2010000150A/es unknown
- 2010-05-21 HN HN2010001062A patent/HN2010001062A/es unknown
- 2010-05-21 CO CO10061059A patent/CO6280409A2/es not_active Application Discontinuation
- 2010-05-21 CR CR11456A patent/CR11456A/es unknown
- 2010-05-21 CU CU2010000098A patent/CU23833A3/es active IP Right Grant
- 2010-05-21 EC EC2010010191A patent/ECSP10010191A/es unknown
- 2010-05-24 MA MA32865A patent/MA31862B1/fr unknown
- 2010-05-25 TN TN2010000234A patent/TN2010000234A1/fr unknown
-
2011
- 2011-03-16 HK HK11102654.0A patent/HK1148541A1/xx unknown
-
2014
- 2014-07-03 JP JP2014137893A patent/JP2014221064A/ja active Pending
-
2015
- 2015-02-10 HK HK15101434.5A patent/HK1200856A1/xx unknown
- 2015-03-11 US US14/645,411 patent/US20150259433A1/en not_active Abandoned
-
2016
- 2016-04-27 CY CY20161100353T patent/CY1117437T1/el unknown
- 2016-05-06 HR HRP20160485TT patent/HRP20160485T1/hr unknown
-
2018
- 2018-03-05 US US15/911,748 patent/US20180258181A1/en not_active Abandoned
- 2018-03-05 JP JP2018038254A patent/JP6717869B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117437T1 (el) | Αντισωματα αντι-μεσοθηλινης και χρησεις αυτων | |
CY1119051T1 (el) | Αντισωματα anti-c4.4a και χρησεις αυτων | |
CY1122627T1 (el) | Αντισωματα εναντι της ceacam6 και χρησεις αυτων | |
CY1119738T1 (el) | Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων | |
CY1116458T1 (el) | Ανθρωπινα αντισωματα anti-cd38 και οι χρησεις εξ' αυτων | |
EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
CY1117236T1 (el) | Μονοκλωνικα αντισωματα εναντι γλυπικανης-3 | |
EA202092735A1 (ru) | Антагонизирующее cd73 антитело | |
CY1119539T1 (el) | Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1 | |
CY1116036T1 (el) | Ανθρωπινα αντισωματα τα οποια δεσμευουν μεσοθηλινη, και χρησεις αυτων | |
CY1113089T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma) | |
EA202090227A1 (ru) | Анти-lag-3 антитело, обладающее повышенной стабильностью | |
EA200970477A1 (ru) | Человеческие моноклональные антитела к btla и способы применения | |
EA201890169A1 (ru) | Тау-связывающие антитела | |
EA201890796A1 (ru) | Новое антитело к мезотелину и содержащая его композиция | |
EA201000238A1 (ru) | Антигенсвязывающие белки для il-18 рецептора и их применение | |
EA201101516A1 (ru) | Антитела, специфические для кадгерина-17 | |
BRPI0808940A8 (pt) | anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor | |
EA201300470A1 (ru) | Антитела | |
CL2009000567A1 (es) | Anticuerpo monoclonal que enlaza especificamente tyrp1 humano; fragmento de cualquiera de los anticuerpos antes indicado; acido nucleico que codifica en anticuerpo o fragmento; vector de expresion; celula recombinante; uso del anticuerpo o fragmento para tratar cancer. | |
EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
MX2011008456A (es) | Anticuerpos anti-mst1r y usos de los mismos. | |
EA200970332A1 (ru) | Новые антигены и антитела, ассоциированные с аденокарциномой панкреатического протока | |
EA202092122A1 (ru) | Антитела против tip-1 и их применения | |
EA201291004A1 (ru) | Пептиды ect2 и включающие их вакцины |